Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANNOAC-AF: NOAC Comparison in Atrial Fibrillation
NCT03129490Phase 4Active, not recruiting
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Apr 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of edoxaban, apixaban, rivaroxaban, dabigatran etexilate oral solution in Atrial fibrillation (AFib), atrial flutter (AFL), sponsored by Herlev & Gentofte Hospital. Started Apr 2023; status: active, not recruiting.
02
Drugs
edoxabanapixabanrivaroxabandabigatran etexilate oral solution
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT03129490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129490.